Literature DB >> 21995409

Long-term outcome of treatment with ruxolitinib in myelofibrosis.

Ayalew Tefferi, Mark R Litzow, Animesh Pardanani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21995409     DOI： 10.1056/NEJMc1109555

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  53 in total

1.  Efficacy of vorinostat in a murine model of polycythemia vera.

Authors:  Hajime Akada; Saeko Akada; Ajeet Gajra; Alicia Bair; Stephen Graziano; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

2.  JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age.

Authors:  Ming Xu; Tamara Tchkonia; Husheng Ding; Mikolaj Ogrodnik; Ellen R Lubbers; Tamar Pirtskhalava; Thomas A White; Kurt O Johnson; Michael B Stout; Vojtech Mezera; Nino Giorgadze; Michael D Jensen; Nathan K LeBrasseur; James L Kirkland
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 3.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 4.  Efficacy of ruxolitinib for myelofibrosis.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2014-05-24       Impact factor: 3.889

Review 5.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

6.  NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Authors:  Collin M Blakely; Evangelos Pazarentzos; Victor Olivas; Saurabh Asthana; Jenny Jiacheng Yan; Irena Tan; Gorjan Hrustanovic; Elton Chan; Luping Lin; Dana S Neel; William Newton; Kathryn L Bobb; Timothy R Fouts; Jeffrey Meshulam; Matthew A Gubens; David M Jablons; Jeffrey R Johnson; Sourav Bandyopadhyay; Nevan J Krogan; Trever G Bivona
Journal:  Cell Rep       Date:  2015-04-02       Impact factor: 9.423

7.  JAK inhibitors: beyond spleen and symptoms?

Authors:  Francisco Cervantes; Ruben Mesa; Claire Harrison
Journal:  Haematologica       Date:  2013-02       Impact factor: 9.941

Review 8.  Advances in myelofibrosis: a clinical case approach.

Authors:  John O Mascarenhas; Attilio Orazi; Kapil N Bhalla; Richard E Champlin; Claire Harrison; Ronald Hoffman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

9.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Authors:  Mohamed Shanavas; Uday Popat; Laura C Michaelis; Veena Fauble; Donal McLornan; Rebecca Klisovic; John Mascarenhas; Roni Tamari; Murat O Arcasoy; James Davies; Usama Gergis; Oluchi C Ukaegbu; Rammurti T Kamble; John M Storring; Navneet S Majhail; Rizwan Romee; Srdan Verstovsek; Antonio Pagliuca; Sumithira Vasu; Brenda Ernst; Eshetu G Atenafu; Ahmad Hanif; Richard Champlin; Paremeswaran Hari; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-19       Impact factor: 5.742

10.  Ruxolitinib: in the treatment of myelofibrosis.

Authors:  Lily P H Yang; Gillian M Keating
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.